{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:30:48Z","timestamp":1780713048929,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T00:00:00Z","timestamp":1228348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s10067-008-1067-x","type":"journal-article","created":{"date-parts":[[2008,12,3]],"date-time":"2008-12-03T09:22:36Z","timestamp":1228296156000},"page":"421-426","source":"Crossref","is-referenced-by-count":27,"title":["Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha"],"prefix":"10.1007","volume":"28","author":[{"given":"Osman","family":"Elbek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neriman","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eermin","family":"B\u00f6rek\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazan","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6ner","family":"Dikensoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,4]]},"reference":[{"key":"1067_CR1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/IAI.73.3.1367-1376.2005","volume":"73","author":"H Cho","year":"2005","unstructured":"Cho H, Lasco TM, Allen SS et al (2005) Recombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages. Infect Immun 73:1367\u20131376","journal-title":"Infect Immun"},{"key":"1067_CR2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.amjmed.2006.01.015","volume":"119","author":"GM Mutlu","year":"2006","unstructured":"Mutlu GM, Mutlu EA, Bellmeyer A et al (2006) Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am J Med 119:639\u2013646","journal-title":"Am J Med"},{"issue":"Suppl","key":"1067_CR3","first-page":"657","volume":"20","author":"HM Vordermeier","year":"1995","unstructured":"Vordermeier HM (1995) T-cell recognition of mycobacterial antigens. Eur Respir J Suppl 20(Suppl):657\u2013667","journal-title":"Eur Respir J Suppl"},{"key":"1067_CR4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","volume":"2","author":"JL Flynn","year":"1995","unstructured":"Flynn JL, Goldstein MM, Chan J et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561\u2013572","journal-title":"Immunity"},{"issue":"Suppl 4","key":"1067_CR5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/ard.2005.042531","volume":"64","author":"S Stenger","year":"2005","unstructured":"Stenger S (2005) Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis 64(Suppl 4):24\u201328","journal-title":"Ann Rheum Dis"},{"key":"1067_CR6","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.4049\/jimmunol.168.3.1328","volume":"168","author":"M Engele","year":"2002","unstructured":"Engele M, St\u00f6ssel E, Castiglione K et al (2002) Induction of TNF in human alveolar macrophages as a potential evasion mechanism of virulent Mycobacterium tuberculosis. J Immunol 168:1328\u20131337","journal-title":"J Immunol"},{"key":"1067_CR7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"MH Schiff","year":"2006","unstructured":"Schiff MH, Burmester GR, Kent JD et al (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889\u2013894","journal-title":"Ann Rheum Dis"},{"key":"1067_CR8","first-page":"85","volume":"2","author":"G K\u0131ter","year":"2001","unstructured":"K\u0131ter G, U\u00e7an ES (2001) Prevention of tuberculosis. Toraks 2:85\u201390","journal-title":"Toraks"},{"key":"1067_CR9","unstructured":"WHO Global Health Atlas (2007) Turkey. http:\/\/www.who.int\/GlobalAtlas\/predefinedReports\/TB\/index.asp?strSelectedCountry=tur Accessed 20 Aug 2007"},{"key":"1067_CR10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.puhe.2005.12.006","volume":"120","author":"SL Ozsahin","year":"2006","unstructured":"Ozsahin SL, Akkurt I, Ozdemir L et al (2006) Are official reports sufficient? Official registration rates of patients with tuberculosis in Sivas, Middle Anatolia. Public Health 120:434\u2013440","journal-title":"Public Health"},{"key":"1067_CR11","first-page":"38","volume":"4","author":"A \u015eakar","year":"2003","unstructured":"\u015eakar A, G\u00f6ktalay T, Da\u011fy\u0131ld\u0131z\u0131 L et al (2003) A tuberculosis screening among school children in Manisa Province. Toraks 4:38\u201342","journal-title":"Toraks"},{"key":"1067_CR12","first-page":"336","volume":"54","author":"\u00c7 Tanr\u0131kulu","year":"2006","unstructured":"Tanr\u0131kulu \u00c7, Abakay A, Abakay \u00d6 et al (2006) Tuberculosis screening results made at primary schools in Cizre. Tuberk Toraks 54:336\u2013340","journal-title":"Tuberk Toraks"},{"key":"1067_CR13","first-page":"163","volume":"3","author":"A\u0130 Bozkurt","year":"2001","unstructured":"Bozkurt A\u0130, Bozkurt N (2001) Gaziantep kent merkezi\u2019nde be\u015f ya\u015f\u0131ndan k\u00fc\u00e7\u00fck \u00e7ocuklarda BCG a\u015f\u0131lama oranlar\u0131. Anadolu T\u0131p Dergisi 3:163\u2013167","journal-title":"Anadolu T\u0131p Dergisi"},{"key":"1067_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tube.2005.01.001","volume":"85","author":"TM Lasco","year":"2005","unstructured":"Lasco TM, Cassone L, Kamohara H et al (2005) Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig. Tuberculosis (Edinb) 85:245\u2013258","journal-title":"Tuberculosis (Edinb)"},{"key":"1067_CR15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"1067_CR16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148\u2013155","journal-title":"Lancet Infect Dis"},{"key":"1067_CR17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14656566.5.3.581","volume":"5","author":"E Toussirot","year":"2004","unstructured":"Toussirot E, Wendling D (2004) The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 5:581\u2013594","journal-title":"Expert Opin Pharmacother"},{"key":"1067_CR18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","volume":"2","author":"KL Winthrop","year":"2006","unstructured":"Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602\u2013610","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1067_CR19","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u00edguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766\u20131772","journal-title":"Arthritis Rheum"},{"key":"1067_CR20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/thx.2005.042457","volume":"60","author":"G Provenzano","year":"2005","unstructured":"Provenzano G, Ferrante MC, Simon G (2005) TB screening and anti-TNF alpha treatment. Thorax 60:613","journal-title":"Thorax"},{"key":"1067_CR21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00000446-200411000-00008","volume":"104","author":"C Bargman","year":"2004","unstructured":"Bargman C (2004) TNF inhibitors and tuberculosis. Am J Nurs 104:15\u201316","journal-title":"Am J Nurs"},{"key":"1067_CR22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1445-5994.2004.00710.x","volume":"34","author":"L Roberts","year":"2004","unstructured":"Roberts L, McColl GJ (2004) Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 34:687\u2013693","journal-title":"Intern Med J"},{"key":"1067_CR23","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR et al (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122\u20132127","journal-title":"Arthritis Rheum"},{"key":"1067_CR24","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","volume":"52","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52:1986\u20131992","journal-title":"Arthritis Rheum"},{"key":"1067_CR25","first-page":"992","volume":"171","author":"H Dunlop","year":"2004","unstructured":"Dunlop H (2004) Infliximab (Remicade) and etanercept (Enbrel): serious infections and tuberculosis. CMAJ 171:992\u2013993","journal-title":"CMAJ"},{"key":"1067_CR26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2169\/internalmedicine.45.1623","volume":"45","author":"K Imaizumi","year":"2006","unstructured":"Imaizumi K, Sugishita M, Usui M et al (2006) Pulmonary infectious complications associated with anti-TNF alpha therapy (infliximab) for rheumatoid arthritis. Intern Med 45:685\u2013688","journal-title":"Intern Med"},{"key":"1067_CR27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10067-008-0867-3","volume":"27","author":"I Hanta","year":"2008","unstructured":"Hanta I, Ozbek S, Kuleci S et al (2008) The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol 27:1083\u20131086","journal-title":"Clin Rheumatol"},{"key":"1067_CR28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","volume":"20","author":"SB Desai","year":"2006","unstructured":"Desai SB, Furst DE (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20:757\u2013790","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1067_CR29","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261\u20131265","journal-title":"Clin Infect Dis"},{"key":"1067_CR30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","unstructured":"British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800\u2013805","journal-title":"Thorax"},{"key":"1067_CR31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2005.040055","volume":"65","author":"BE Joven","year":"2006","unstructured":"Joven BE, Almodovar R, Galindo M et al (2006) Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response? Ann Rheum Dis 65:699","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-008-1067-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-008-1067-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-008-1067-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T02:27:48Z","timestamp":1738722468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-008-1067-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s10067-008-1067-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,4]]}}}